InsidersTradesSigma
Tekla Healthcare Opportunities Fund Stock: price and management transactions · United States · SEC (Form 4)
Follow the Tekla Healthcare Opportunities Fund stock price and the full insider trade history of the company, a listed equity based in United States. Shares are quoted on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Tekla Healthcare Opportunities Fund has logged 2 insider filings. Market capitalisation: €792.7m. The latest transaction was reported on 24 March 2022 (Acquisition). Among the most active insiders: Goetz Kathleen. The full history is free.
2
Insider Decl.
0
Thresholds
€10,568
2 ops.
Buy Volume
·
0 ops.
Sell Volume
20Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 24 March 2022
Declarations2 total
69.188 shares@ US$21.6850.0002% mcap6.9% of flowShares of Beneficial InterestSEC:0001104659-22-037467:0
Ideal exit: 18 Dec 2022 (T+270)
479 shares@ US$21.730.0013% mcap46.6% of flowShares of Beneficial InterestSEC:0001104659-22-008201:0
Ideal exit: 23 Oct 2022 (T+270)
2 of 2 declarations
About Tekla Healthcare Opportunities Fund
Tekla Healthcare Opportunities Fund is a U.S.-listed closed-end investment fund traded on the NYSE under the ticker THQ. For international investors, it is important to note that THQ is not an operating healthcare company; it is a specialized investment vehicle organized as a Massachusetts business trust and registered as a non-diversified closed-end management investment company. The fund was formed on April 2, 2014 and is headquartered in Boston, Massachusetts, at 100 Federal Street, 19th Floor. Historically part of the Tekla family of healthcare funds, THQ was previously managed by Tekla Capital Management LLC and then transferred to abrdn effective October 27, 2023, which is the most significant recent structural development. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1604522/000110465922068023/tm228077d1_ncsrs.htm?utm_source=openai)) From an investment standpoint, Tekla Healthcare Opportunities Fund seeks current income and long-term capital appreciation by investing in companies engaged in the healthcare industry. Its mandate is broad and opportunistic: the fund may allocate across healthcare equities, debt securities, and pooled investment vehicles, with exposure that can extend to biotechnology, healthcare technology, medical devices, and adjacent healthcare-related segments. This broad remit gives the portfolio manager flexibility to shift between sub-industries and capital structures, rather than relying on a single healthcare bet. ([abrdn.com](https://www.abrdn.com/docs?editionid=2bcf5c9d-48e2-4add-b918-b02d0104d164&utm_source=openai)) In competitive terms, THQ occupies a niche within U.S. listed healthcare closed-end funds. Its distinction lies in the combination of a daily traded NYSE listing and an active, income-oriented healthcare strategy. Compared with open-end mutual funds or passive ETFs, a closed-end fund can trade at a discount or premium to net asset value, which introduces a separate valuation dimension that investors should monitor. This structure makes THQ relevant both as a thematic healthcare allocation and as a market-traded income instrument. ([beta.nyse.com](https://beta.nyse.com/products/exchange-traded-products/closed-end-funds?utm_source=openai)) Recent highlights center on the 2023 change of investment adviser to abrdn, which assumed responsibility for THQ and the other former Tekla closed-end funds. Current abrdn materials also show continued quarterly distribution activity, underscoring the fund’s role as a cash-yielding healthcare exposure on the NYSE. For investors in France, Belgium, and Switzerland, THQ should therefore be viewed primarily as a listed U.S. healthcare income fund rather than as a conventional healthcare operator. ([sec.gov](https://www.sec.gov/Archives/edgar/data/805267/000110465924069986/tm2416006d9_ncsrs.htm?utm_source=openai))
